| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 2025-090 | | --- | --- | --- | | | | 号 | | 债券简称：华海转债 | 债券代码：110076 | | 关于下属子公司产品被纳入优先审评品种名单的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，根据国家药品监督管理局药品审评中心（以下简称"CDE"）发布的公示 信息，浙江华海药业股份有限公司（以下简称"华海药业"或"公司"）下属子公司 上海华奥泰生物药业股份有限公司（以下简称"华奥泰"）自主研发的瑞西奇拜单抗 （研发代号为：HB0034）注射液被纳入优先审评审批程序的品种名单。根据《国家 药监局关于发布突破性治疗药物审评工作程序（试行）等三个文件的公告》（2020 年 第 82 号）有关要求，CDE 对纳入优先审评审批程序的药品上市许可申请，按注册申 请受理时间顺序优先配置资源进行审评。现将相关情况公告如下： 一、药物基本情况 药物名称：瑞西奇拜单抗注射液 剂型：注射剂 拟定适应症：用于治疗成人泛发性脓 ...

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has decided not to lower the conversion price of its convertible bonds, Huahai Convertible Bonds, despite the stock price falling below the threshold for adjustment [1][4][14]. Group 1: Board Meeting and Decisions - The third temporary meeting of the ninth board of directors was held on August 15, 2025, with all nine directors present, meeting the legal requirements for the meeting [1]. - The board unanimously approved the proposal not to lower the conversion price of the Huahai Convertible Bonds [1][4]. Group 2: Convertible Bond Details - As of August 15, 2025, the company's stock price had been below 80% of the current conversion price for at least 15 trading days within any 30 consecutive trading days, triggering the adjustment clause [4][13]. - The initial conversion price was set at 34.66 CNY per share, with the latest conversion price adjusted to 33.06 CNY per share [5][9]. - The company issued 18.426 million convertible bonds with a total amount of 1.8426 billion CNY, with a maturity of six years from the issuance date [5]. Group 3: Future Considerations - The board will not propose a downward adjustment for the conversion price in the next two months (from August 16 to October 15, 2025), even if the adjustment clause is triggered again [4][14]. - Starting from October 16, 2025, if the adjustment clause is triggered again, the board will convene to consider whether to exercise the right to adjust the conversion price [5][14].

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. held its third temporary meeting of the ninth board of directors on August 15, 2025, where it was decided not to lower the conversion price of the "Huahai Convertible Bonds" [1]. Group 1 - The meeting was attended by all nine directors, meeting the legal quorum requirements [1]. - The resolution regarding the non-adjustment of the conversion price for the "Huahai Convertible Bonds" was passed unanimously with 9 votes in favor and no votes against or abstentions [1]. - The details of the resolution will be published in various financial newspapers and on the Shanghai Stock Exchange website [1].

Core Viewpoint - Huahai Pharmaceutical (600521) announced that its board of directors decided not to exercise the right to lower the conversion price of "Huahai Convertible Bonds" for the current period and will not propose a downward adjustment in the next two months [1] Group 1 - The board resolution was made during the third temporary meeting of the ninth board of directors [1] - The period for potential downward adjustment of the conversion price is set from August 16, 2025, to October 15, 2025 [1] - Starting from October 16, 2025, the company will reassess whether to exercise the right to adjust the conversion price if the conditions are met [1]

Group 1 - The core point of the article is that Huahai Pharmaceutical announced the decision not to adjust the conversion price of its "Huahai Convertible Bonds" during the third temporary meeting of the ninth board of directors [2]

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 | 2025-089 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 关于不向下修正"华海转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至 2025 年 8 月 15 日，浙江华海药业股份有限公司（以下简称"公司"） 股价已出现任意三十个连续交易日中至少十五个交易日收盘价格低于当期转股 价格 80%的情形，触及"华海转债"转股价格向下修正条款。 经公司第九届董事会第三次临时会议审议通过，公司董事会决议本次不行使 "华海转债"转股价格向下修正的权利，且在未来 2 个月内（2025 年 8 月 16 日 至 2025 年 10 月 15 日），如再次触及可转债的转股价格向下修正条款，亦不提出 向下修正方案。从 2025 年 10 月 16 日开始重新起算，若再次触发"华海转债" 转股价格向下修正 ...

债券简称：华海转债 债券代码：110076 股票简称：华海药业 股票代码：600521 公告编号：临 2025-088 号 浙江华海药业股份有限公司 第九届董事会第三次临时会议决议公告 一、审议通过了《关于不向下修正"华海转债"转股价格的议案》 表决情况：同意：9 票；反对：0 票；弃权：0 票。 具体内容详见公司于 2025 年 8 月 16 日刊登在中国证券报、上海证券报、证券 时报、证券日报及上海证券交易所网站（www.sse.com.cn）上的《浙江华海药业股 份有限公司关于不向下修正"华海转债"转股价格的公告》。 特此公告。 浙江华海药业股份有限公司 董事会 二零二五年八月十五日 1 / 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下称"公司"）第九届董事会第三次临时会议于 二零二五年八月十五日下午十五点以通讯方式在公司四楼会议室召开。会议应到会 董事九人，实际到会董事九名，符合召开董事会会议的法定人数。会议由公司董事 长李宏先生主持。会议程序符合《公司法》及《公司章程》的规 ...

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has established a new subsidiary, Huahai Tianheng (Shanghai) Pharmaceutical Research Co., Ltd., with an investment of 400 million RMB, focusing on research and experimental development in the pharmaceutical industry [1] Company Summary - Huahai Tianheng (Shanghai) Pharmaceutical Research Co., Ltd. was founded on September 23, 2024, with a registered capital of 400 million RMB and is wholly owned by Zhejiang Huahai Pharmaceutical Co., Ltd. [1] - The company is located in Shanghai and is involved in various activities including medical research and experimental development, import and export of goods and technology, data processing and storage support services, and various technical services [1] - The company is authorized to engage in several licensed activities such as drug production, wholesale, retail, import and export, contract manufacturing, and clinical trial services, subject to regulatory approvals [1] Industry Summary - The establishment of Huahai Tianheng indicates a strategic move within the pharmaceutical industry, emphasizing the importance of research and development in enhancing the company's capabilities and market position [1]

Core Viewpoint - The article discusses the approval and details of the Guangdong Province Synthetic Biology Manufacturing Pilot Platform Project, highlighting its investment, construction scale, and the upcoming SynBioCon 2025 conference focused on synthetic biology and green manufacturing trends [3][4][5]. Project Approval and Details - The Guangdong Provincial Development and Reform Commission approved the preliminary design budget for the Synthetic Biology Manufacturing Pilot Platform Project, with a total investment of 21,733,000 yuan, including engineering costs of 19,459,000 yuan and other expenses [3]. - The project will establish four major pilot platforms: an intelligent microbial pilot platform, a functional macromolecule pilot platform, a green biomass methanol pilot platform, and an intelligent plant pilot platform, covering a construction area of approximately 8,500 square meters and acquiring about 365 sets of instruments and equipment [3][4]. SynBioCon 2025 Conference - The SynBioCon 2025 conference will be held from August 20 to 22 in Ningbo, Zhejiang, focusing on four main areas: AI in biological manufacturing, green chemical engineering and new materials, future food, and future agriculture [5]. - The conference aims to explore the development trends of the biological manufacturing industry during the 14th Five-Year Plan, innovations driven by AI, and the continuous vitality brought by new technologies and products [5]. - Various activities will take place during the conference, including a youth forum, high-level discussions, and a closed-door seminar on the "2025 Blue Book for AI Empowering Biological Manufacturing Industry Innovation" [5][11].

Group 1 - The company, Zhejiang Huahai Pharmaceutical Co., Ltd., has issued convertible bonds with a total amount of 1,842.60 million bonds, each with a face value of 100.00 yuan, totaling 184,260.00 million yuan [3] - The convertible bond, referred to as "Huahai Convertible Bond," is listed on the Shanghai Stock Exchange with the code "110076" and has a maturity period of six years from the issuance date [3] - The conversion price for the bonds is set at 33.06 yuan per share, with the conversion period running from May 6, 2021, to November 1, 2026 [2] Group 2 - The company anticipates that the conditions for a downward adjustment of the conversion price may be triggered, as the stock price has been below 80% of the current conversion price for 10 trading days within a 30-day period [6] - If the downward adjustment condition is triggered, the company will convene a board meeting to decide whether to adjust the conversion price and will disclose the decision in a timely manner [6][5] - The adjustment process requires a two-thirds majority approval from shareholders present at the meeting, excluding those holding the convertible bonds [4] Group 3 - The company has previously announced on April 26, 2025, that it would not adjust the conversion price of the "Huahai Convertible Bond" [6] - The company is obligated to disclose any decisions regarding the adjustment of the conversion price in accordance with the regulations set by the Shanghai Stock Exchange [6][5] - Investors can refer to the prospectus published on October 29, 2020, for more information regarding the "Huahai Convertible Bond" [7]